Table 1.
A Summary of the Characteristics of our Cohort. The continuous variables are shown as median (interquartile range), frequency data as absolute frequency (relative frequency). The p values show significance based on Fisher’s exact test or Chi-square test for relative frequency, or on the Student’s t-test for continuous variables, comparing patients using antiplatelet therapy vs. patients without antiplatelet therapy.
| Parameters | All Patients | Patients without Antiplatelet Therapy | Patients Using Antiplatelet Therapy | P Value |
|---|---|---|---|---|
| Gender | Males 75 (49%) Females 77 (51%) |
Males 53 (46%) Females 61 (54%) |
Males 22 (58%) Females 16 (42%) |
0.1193 |
| Age, years | 75.5 (22.75) | 72.5 (24.8) | 80.5 (11.3) | 0.0003 ∗∗∗ |
| Overweight | yes 69 (51%) no 67 (49%) |
yes 53 (51%) no 50 (49%) |
yes 16 (48%) no 17 (52%) |
0.7774 |
| Cardiac Conduction Abnormalities | Atrial fibrillation 37 (25%) Other abnormality 10 (7%) None 104 (69%) |
Atrial fibrillation 30 (26%) Other abnormality 5 (4%) None 79 (69%) |
Atrial fibrillation 9 (24%) Other abnormality 3 (8%) None 25 (68%) |
0.4927 |
| Hypertension | 103 (68%) | 69 (61%) | 34 (89%) | <0.0001 ∗∗∗ |
| Diabetes Mellitus | 51 (34%) | 38 (33%) | 13 (34%) | >0.9999 |
| Chronic Lung Conditions | COPD 18 (12%) Asthma 2 (1%) Silicosis 1 (1%) |
COPD 14 (13%) Silicosis 1 (1%) |
COPD 4 (10%) Asthma 2 (5%) |
0.0938 |
| Heart Failure or Coronary Artery Disease | 52 (34%) | 22 (19%) | 30 (79%) | <0.0001 ∗∗∗ |
| Malignancy | 29 (19%) | 16 (14%) | 13 (34%) | 0.0015 ∗∗ |
| Stroke | 15 (10%) | 8 (7%) | 7 (18%) | 0.0309 ∗ |
| Limb Ischemia | 15 (10%) | 5 (4%) | 10 (28%) | <0.0001 ∗∗∗ |
| Use of Angiotensin II Receptor Blockers | 32 (21%) | 22 (19%) | 10 (26%) | 0.3096 |
| Use of ACE Inhibitors | 36 (24%) | 22 (19%) | 14 (37%) | 0.0071 ∗∗ |
| Use of Statins | 39 (26%) | 19 (17%) | 20 (53%) | <0.0001 ∗∗∗ |
| Antiplatelet Medications | Total 38 (25%) ASA 35 (23%) clopidogrel 3 (2%) |
n/a | ASA 35 (92%) clopidogrel 3 (8%) | n/a |
| Anticoagulants | Coumarins 4 (2.6%) NOACs 27 (17.8%) |
Coumarins 3 (3%) NOACs 20 (18%) |
Coumarins 1 (3%) NOACs 7 (18%) |
>0.9999 |
| Nasopharyngeal Swab with a PCR Test | Positive 100 (70%) Negative 43 (30%) |
Positive 71 (56%) Negative 37 (34%) |
Positive 29 (83%) Negative 6 (17%) |
0.0017 ∗∗ |
| CT/chest X-ray | Positive 117 (77%) Negative 34 (23%) |
Positive 83 (73%) Negative 30 (27%) |
Positive 34 (89%) Negative 4 (11%) |
0.0063 ∗∗ |
| Length of Stay,in days | 9.0 (7.0) | 9.0 (6.8) | 11.5 (8.5) | 0.0153 ∗ |
| Mechanical Ventilation | None 131 (86%) Non-invasive 4 (3%) Invasive 18 (12%) |
None 99 (87%) Non-invasive 4 (4%) Invasive 11 (10%) |
None 32 (84%) Invasive 6 (16%) |
0.0661 |
| Troponin | Positive 23 (27%) Negative 61 (73%) |
Positive 15 (23%) Negative 49 (77%) |
Positive 8 (40%) Negative 12 (60%) |
0.0145 ∗ |
| D-Dimer, μg/ml | 1.230 (1.225) | 0.91 (1.04) | 1.95 (1.68) | 0.0048 ∗∗ |
| Minimum Leukocyte Count, x 1000 per μl | 5.4 (2.8) | 5.35 (2.63) | 5.90 (3.18) | 0.5644 |
| Maximum Leukocyte Count, x 1000 per μl | 8.3 (5.7) | 7.90 (5.50) | 9.95 (5.45) | 0.5957 |
| Maximum Lactate Dehydrogenase Level, units/l | 401 (225) | 394 (234) | 425 (239) | 0.4940 |
| Minimum CRP Level, mg/l | 16.5 (33.7) | 16.5 (33.5) | 18.5 (31.8) | 0.3046 |
| Maximum CRP Level, mg/l | 85.5 (131) | 84.0 (126) | 100.0 (169) | 0.0564 |
| Patient Outcomes | Discharged 127 (84%) Referred 6 (4%) Deceased 19 (13%) |
Discharged 91 (80%) Referred 5 (4%) Deceased 18 (16%) |
Discharged 30 (79%) Referred 1 (3%) Deceased 7 (18%) |
0.8751 |